Literature DB >> 19349521

Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.

John Huggins1, Arthur Goff, Lisa Hensley, Eric Mucker, Josh Shamblin, Carly Wlazlowski, Wendy Johnson, Jennifer Chapman, Tom Larsen, Nancy Twenhafel, Kevin Karem, Inger K Damon, Chelsea M Byrd, Tove' C Bolken, Robert Jordan, Dennis Hruby.   

Abstract

ST-246, a potent orthopoxvirus egress inhibitor, is safe and effective at preventing disease and death in studies of small-animal models involving challenge by several different pathogenic poxviruses. In this report, the antiviral efficacy of ST-246 in treatment of nonhuman primates infected with variola virus or monkeypox virus was assessed. The data indicate that oral dosing once per day with ST-246 protects animals from poxvirus disease, as measured by reductions in viral load and numbers of lesions and enhancement of survival.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19349521      PMCID： PMC2687232          DOI： 10.1128/AAC.00021-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  22 in total

1.  Dramatic rescue relieves rare case of smallpox infection.

Authors:  Emma Marris
Journal:  Nat Med       Date:  2007-04-26       Impact factor: 53.440

Review 2.  Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  D A Henderson; T V Inglesby; J G Bartlett; M S Ascher; E Eitzen; P B Jahrling; J Hauer; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  1999-06-09       Impact factor: 56.272

3.  Clinical characteristics of human monkeypox, and risk factors for severe disease.

Authors:  Gregory D Huhn; Audrey M Bauer; Krista Yorita; Mary Beth Graham; James Sejvar; Anna Likos; Inger K Damon; Mary G Reynolds; Matthew J Kuehnert
Journal:  Clin Infect Dis       Date:  2005-11-11       Impact factor: 9.079

Review 4.  Smallpox: a potential agent of bioterrorism.

Authors:  Richard J Whitley
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 5.970

5.  Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001.

Authors:  Hermann Meyer; Mathilde Perrichot; Markus Stemmler; Petra Emmerich; Herbert Schmitz; Francis Varaine; Robert Shungu; Florimond Tshioko; Pierre Formenty
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

6.  Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.

Authors:  Peter B Jahrling; Lisa E Hensley; Mark J Martinez; James W Leduc; Kathleen H Rubins; David A Relman; John W Huggins
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

7.  Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.

Authors:  Patricia L Earl; Jeffrey L Americo; Linda S Wyatt; Leigh Anne Eller; J Charles Whitbeck; Gary H Cohen; Roselyn J Eisenberg; Christopher J Hartmann; David L Jackson; David A Kulesh; Mark J Martinez; David M Miller; Eric M Mucker; Joshua D Shamblin; Susan H Zwiers; John W Huggins; Peter B Jahrling; Bernard Moss
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

8.  An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.

Authors:  Guang Yang; Daniel C Pevear; Marc H Davies; Marc S Collett; Tom Bailey; Susan Rippen; Linda Barone; Chris Burns; Gerry Rhodes; Sanjeev Tohan; John W Huggins; Robert O Baker; R L Mark Buller; Erin Touchette; Kem Waller; Jill Schriewer; Johan Neyts; Erik DeClercq; Kevin Jones; Dennis Hruby; Robert Jordan
Journal:  J Virol       Date:  2005-10       Impact factor: 6.549

9.  Severe eczema vaccinatum in a household contact of a smallpox vaccinee.

Authors:  Surabhi Vora; Inger Damon; Vincent Fulginiti; Stephen G Weber; Madelyn Kahana; Sarah L Stein; Susan I Gerber; Sylvia Garcia-Houchins; Edith Lederman; Dennis Hruby; Limone Collins; Dorothy Scott; Kenneth Thompson; John V Barson; Russell Regnery; Christine Hughes; Robert S Daum; Yu Li; Hui Zhao; Scott Smith; Zach Braden; Kevin Karem; Victoria Olson; Whitni Davidson; Giliane Trindade; Tove Bolken; Robert Jordan; Debbie Tien; John Marcinak
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 20.999

10.  Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model.

Authors:  Aysegul Nalca; Josh M Hatkin; Nicole L Garza; Donald K Nichols; Sarah W Norris; Dennis E Hruby; Robert Jordan
Journal:  Antiviral Res       Date:  2008-04-23       Impact factor: 10.103
View more
  60 in total

1.  Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.

Authors:  M S Keckler; D S Carroll; N F Gallardo-Romero; R R Lash; J S Salzer; S L Weiss; N Patel; C J Clemmons; S K Smith; C L Hutson; K L Karem; I K Damon
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

3.  Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.

Authors:  Graham J Hatch; Victoria A Graham; Kevin R Bewley; Julia A Tree; Mike Dennis; Irene Taylor; Simon G P Funnell; Simon R Bate; Kimberley Steeds; Thomas Tipton; Thomas Bean; Laura Hudson; Deborah J Atkinson; Gemma McLuckie; Melanie Charlwood; Allen D G Roberts; Julia Vipond
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

4.  Exposure of rhesus monkeys to cowpox virus Brighton Red by large-particle aerosol droplets results in an upper respiratory tract disease.

Authors:  Reed F Johnson; Dima A Hammoud; Donna L Perry; Jeffrey Solomon; Ian N Moore; Matthew G Lackemeyer; Jordan K Bohannon; Philip J Sayre; Mahnaz Minai; Amy B Papaneri; Katie R Hagen; Krisztina B Janosko; Catherine Jett; Kurt Cooper; Joseph E Blaney; Peter B Jahrling
Journal:  J Gen Virol       Date:  2016-05-09       Impact factor: 3.891

5.  A novel respiratory model of infection with monkeypox virus in cynomolgus macaques.

Authors:  Arthur J Goff; Jennifer Chapman; Chad Foster; Carly Wlazlowski; Joshua Shamblin; Kenny Lin; Norman Kreiselmeier; Eric Mucker; Jason Paragas; James Lawler; Lisa Hensley
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

6.  A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012.

Authors:  Scott Parker; R Mark Buller
Journal:  Future Virol       Date:  2013-02-01       Impact factor: 1.831

7.  Intrabronchial inoculation of cynomolgus macaques with cowpox virus.

Authors:  Alvin L Smith; Marisa St Claire; Srikanth Yellayi; Laura Bollinger; Peter B Jahrling; Jason Paragas; Joseph E Blaney; Reed F Johnson
Journal:  J Gen Virol       Date:  2011-09-21       Impact factor: 3.891

8.  Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.

Authors:  Donald F Smee
Journal:  Future Virol       Date:  2013-09       Impact factor: 1.831

9.  Retrograde Transport from Early Endosomes to the trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virus Virions.

Authors:  Gilad Sivan; Andrea S Weisberg; Jeffrey L Americo; Bernard Moss
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents.

Authors:  Chad J Roy; Thomas G Voss
Journal:  Viruses       Date:  2010-09-27       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.